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Abstract: Dihydropyridine Ca2+ channel blockers (CCBs) are widely accepted in the 
treatment of premature labour. Their mechanism of action in tocolysis involves the blockade 
of L-type Ca2+ channels, influenced by the Ca2+-activated K+ channels, beta-adrenergic 
receptors (β-ARs) and sexual hormones. In clinical practice, most experience has been 
gained with the use of nifedipine, whose efficacy is superior or comparable to those of  
β-agonists and oxytocin antagonists. Additionally, it has a favourable adverse effect profile 
as compared with the majority of other tocolytics. The most frequent and well-tolerated 
side-effects of CCBs are tachycardia, headache and hypotension. In tocolytic therapy 
efforts are currently being made to find combinations of tocolytic agents that yield better 
therapeutic action. The available human and animal studies suggest that the combination of 
CCBs with β-AR agonists is beneficial, although such combinations can pose risk of 
pulmonary oedema in multiple pregnancies and maternal cardiovascular diseases. 
Preclinical data indicate the potential benefit of combinations of CCBs and oxytocin 
antagonists. However, the combinations of CCBs with progesterone or cyclooxygenase 
inhibitors may decrease their efficacy. The CCBs are likely to remain one of the most 
important groups of drugs for the rapid inhibition of premature uterine contractions. Their 
significance may be magnified by further clinical studies on their combined use for tocolysis. 
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Pre-term birth (PTB) is one of the main clinical problems in obstetrical practice. The incidence of 
PTB may differ in different regions, the rate varying worldwide in the range between 5–11% [1]. 
Despite of the availability of several drugs that inhibit pre-term contractions (tocolytics), the 
pharmacotherapy of PTB is inappropriate. Additionally, the maternal and foetal side-effects caused by 
high doses of such drugs may induce further complications; there is therefore a great need for effective 
and well-tolerated drugs against PTB. Ca2+ channel blockers (CCBs), and especially nifedipine and 
nicardipine, are among the frequently used tocolytics. They are constantly gaining in importance, and 
increasingly more significant than traditional tocolytics such as beta-adrenergic receptor (β-AR) 
blockers or magnesium sulphate. Although they do not meet the criteria of ideal tocolytics, CCBs have 
certain properties that make them preferable to other tocolytics. Haas et al. concluded that CCBs have 
high probability of delaying PTB and improving neonatal outcomes [2]. 
2. The Mechanism of Action of CCBs on the Pregnant Myometrium 
Uterine contractile activity is regulated by the increase in intracellular Ca2+ concentration in the 
myometrial cells. Voltage-gated Ca2+ channels (VGCCs) mediate the Ca2+ influx in response to 
membrane depolarization and regulate intracellular processes such as contraction [3,4]. Ca2+ binds to 
calmodulin and activates the myosin light chain kinase (MLCK) in the myometrial cells and therefore 
leads to the phosphorylation of serine 19 on myosin light chains and initiates subsequent cross-bridge 
cycling. There are two sources for the increase in activator Ca2+: entry across the surface membrane 
through VGCCs and/or release from the sarcoplasmic reticulum. In the uterus, where the action 
potential occurs, the resulting depolarization and consequent opening of the VGCCs make this the 
major source of Ca2+ for contraction. Each contraction is accompanied by a Ca2+ transient in the uterus, 
and both transients and contractions are abolished if the VGCCs are blocked [5–7]. 
The voltage dependent L-type calcium channels have been identified in uterine myometrium by 
electrophysiological, pharmacological and molecular studies [8]. They are responsible for the majority 
of the observed calcium current in the human myometrium. The Ca2+ channels are complex proteins 
composed of five distinct subunits (α1, α2, β, δ and γ) encoded by multiple genes [3]. Dihydropyridines 
(DHPs) such as nifedipine bind to the DHP binding side of the VG L-type channels, which is located 
on the α1 subunit. The channels have several isoforms resulting from alternative splicing sites of the 
α1 subunit [9,10]. The increased expression of one of the VGCC isoforms (S3B) was detected in 
pregnant rat myometrium during labour [11]. In guinea pigs, Collins et al. [8] have demonstrated 
significant changes in the expression of the α1 subunit of L-type VGCCs in pregnancy and labour. An 
increase in DHP binding capacity was seen through the last half of gestation which supports the role of 
L-type VGCCs in the process of parturition. 
The CCBs therefore arouse considerable interest for both therapeutic and experimental purposes [12]. 
The activity and sensitivity of L-type Ca2+ channels to DHP CCBs are influenced by at least three factors. 
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2.1. Factor 1: Ca2+-Activated K+ (BKCa) Channels 
The uterus contains BKCa channels and their expression and distribution have been shown to be 
gestation-regulated [13]. The BKCa channels are a diverse group of K+ channels that participate in the 
repolarization and hyperpolarization of action potentials. They are activated by elevated intracellular 
Ca2+ levels. The opening of BKCa channels is associated with small hyperpolarizations, which lead  
to the decreased opening of L-type Ca2+ channels and a fall in Ca2+ concentration, and hence to 
relaxation [5,14,15]. The role of BKCa channels in combination with nifedipine was investigated by 
Moynihan et al. [16], who concluded that the BKCa channel blockers significantly antagonize the 
relaxant effect of nifedipine. However, another study, with paxilline and tetraethylammonium, 
indicated that the BKCa channels and any other K+ channel, in contrast with human myometrium, are 
not involved in the relaxing effect of nifedipine in the pregnant rat myometrium [17]. 
2.2. Factor 2: Beta-Adrenergic Receptors 
The adrenergic system plays an important role in the control of uterine contractility. Currently,  
β2-AR agonists are still among the most frequently used tocolytics, although their therapeutic 
significance in PTB is constantly questioned. 
β-AR stimulants are known to produce smooth muscle cell relaxation by activating Gs proteins, and 
their Gαs subunit stimulates adenyl cyclase. This elevates the level of cyclic adenosine monophosphate 
(cAMP), which activates protein kinase A, this activated form inducing phosphorylation of the Ca2+ 
channels. This mechanism is well known in the heart muscle [18] and may be similar to that in the 
pregnant myometrium. One of the first studies of the effects of combinations of β2-agonists and CCBs 
was reported by Lever et al. [19]. The literature data show that both isradipine and nifedipine 
potentiate the relaxant action of terbutaline and salmeterol in the isolated trachea [20]. Together, these 
results suggest an increased relaxant effect of β2-agonists combined with CCBs in the pregnant 
myometrium. The efficacy of a β2-AR agonist and a CCB in the pregnant myometrium has been 
investigated both in vitro and in vivo. Synergism has been observed in the uterus-relaxing effect of 
nifedipine and the β2-AR agonist terbutaline, although the extent of potentiation depends on the 
sequence of administration of the two compounds. Terbutaline possibly activates the Cav1.2 channels 
and decreases the maximum relaxing effect of nifedipine. The resultant effect of the increase in cAMP 
level and the activation of Cav1.2 channels cause a weaker smooth muscle relaxation. In the opposite 
case, when nifedipine is administered first, the Cav1.2 channels are blocked, hence terbutaline cannot 
activate them [21]. 
2.3. Factor 3: Progesterone 
Another factor which regulates the L-type Ca2+ channel is the progesterone (P4)/oestrogen (E2) 
ratio [22]. P4 is a key component in the complex regulation of the normal female reproductive function. 
It plays a central role in the maintenance of pregnancy and in the initiation of parturition by modulating 
myometrial contractility and excitability. P4 supports pregnancy and prevents parturition by promoting 
myometrial quiescence [23,24]. The level of P4 normally declines at term prior to the development of 
labour, and P4 has therefore also been used as prophylaxis in the prevention of PTB [25–28]. 
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Combinations of P4 and β2-AR agonists have also been investigated in the pregnant myometrium. 
P4 pre-treatment increases the expression of the β2-AR during pregnancy and alters the effects of  
β2-AR agonists on the pregnant myometrium; P4 and its derivatives have been considered as drugs 
against PTB [23,29]. 
It was been demonstrated that the mRNA expression of the pore-forming α1C subunit of the L-type 
Ca2+ channel is regulated by glucocorticoid hormones, but tissue-specific changes may occur [30]. 
Biochemical experiments have detected the presence of two forms of the L-type Ca2+ channel in native 
tissues: a short form (α1C-short) and a long (α1C-long) form. Helguera et al. [22] established that a  
P4-mediated mechanism favours the expression of the long form, in the presence of which the channel 
displays lower activity. We earlier observed [21] that in vivo P4 pre-treatment (for 7 days) decreased 
the maximum inhibitory effect of nifedipine and increased its EC50 in vitro, and also abolished the 
ability of nifedipine to delay labour in hormone-induced pre-term delivery in rats in vivo [31]. These 
results correlate with the hypothesis that P4 decreases the activity of the L-type Ca2+ channels. 
However, Baumbach et al. [32] reported that P4 increased the relaxing effect of nifedipine on the 
human myometrium in vitro. In that study, P4 was added directly to the tissue bath. It is known that the 
prompt action of P4 on the contractility of the smooth muscles is not caused by genomic effects 
through a receptor-mediated mechanism, but by direct effects on the plasma membrane [33]. The 
manners in which the three factors influence the L-type Ca2+ channels mentioned above are presented 
in Table 1. 
Table 1. Influence of some physiological factors on L-type Ca2+ channels in the pregnant myometrium. 




presumably increases the tocolytic 
effect of CCBs 
β-AR activation opening increases the tocolytic effect of CCBs 
Long-term 
progesterone effect 
expression of less sensitive 
form 
presumably decreases the tocolytic 
effect of CCBs 
3. The Efficacy of CCBs against PTB 
A number of drugs are used against threatening PTB, although only oxytocin antagonists have been 
designed specifically as tocolytic medication (Table 2). Thus, DHP CCBs are utilized for this purpose, 
but they have not been licensed for tocolysis. Many data demonstrate the efficacy of nifedipine, 
whereas little information is available on the action of nicardipine in PTB. 
Nifedipine is used orally for both tocolysis and cardiovascular treatment. The appropriate dose of 
nifedipine for tocolysis is still under investigation. In a comparison of two dose regimens of oral 
nifedipine in a study on threatening PTB between gestational weeks 24 and 34, it was found that a high 
dose of the drug (20 mg loading dose, daily 120–160 mg for 48 hours, followed by 80–120 mg daily 
up to 36 weeks) did not have any advantage over a low dose (10 mg loading dose, daily 60–80 mg for 
48 hours, followed by 60 mg daily up to 36 weeks) as regards uterine quiescence [34]. In a small 
Bulgarian study, nifedipine (40 mg four times daily) delayed a large majority of the pregnancies (32 
out of 41) with early contractions until normal term, without significant side-effects [35]. 
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Table 2. Class of drugs used clinically for tocolysis. 




Maternal: tachycardia, hyperglycemia, 
pulmonary oedema 
Foetal: tachycardia, RDS 
Cyclooxygenase 
inhibitors 
inflammation, pain, fever 
Foetal: premature closure of ductus arteriosus, 
reduced amniotic fluid index 
Gestagens hormonal substitution, contraception no relevant side effect 
Magnesium sulphate 
hypomagnesaemia, eclampsia in 
pregnancy  
Maternal: constipation, visual blurring, 
headache 
CCBs (DHPs) hypertension  Maternal: headache, tachycardia, hypotension 
Oxytocin antagonists tocolysis Maternal: tachycardia, chest pain 
There have been reports of the lack of action of nifedipine in premature contractions. A placebo-
controlled, randomized trial demonstrated that 20 mg of nifedipine administered every 4–6 hours did 
not maintain pregnancy or delay delivery as compared with the placebo group [36]. In a recent trial, 
nifedipine-maintained tocolysis (80 mg/day orally for 12 days) did not result in a statistically 
significant reduction in adverse perinatal outcome or in a significantly lengthened gestational duration 
in patients with threatening PTB, although the rate of adverse perinatal outcome was lower as 
compared with the control group [37]. This result suggests that the use of nifedipine does not significantly 
delay labour. 
In twin pregnancies where nifedipine tocolysis was administered a switchover to subcutaneous 
terbutaline following hospitalization for recurrent symptoms of the threatening PTB had a positive 
impact on pregnancy prolongation and on the neonatal outcome [38]. 
In another investigation, nifedipine was found to be more effective than indomethacin in inhibiting 
uterine contractions during the first 2 hours; however, there was no difference between indomethacin 
and nifedipine in delaying delivery for up to 7 days [39]. 
Atosiban and nifedipine have been shown not to significantly differ in delaying delivery [40,41]. 
This limited evidence suggests no essential differences in the tocolytic efficacy of these two drugs. The 
oral administration, the lower costs and the possibly lower level of neonatal morbidity favour the use 
of nifedipine [42,43]. 
Nicardipine has the advantageous feature over nifedipine that its intravenous administration is 
possible, and it is the first choice for some obstetricians in the management of PTB. However, 
intravenous nicardipine does not increase the duration of pregnancy in comparison with oral 
nifedipine. The median duration between treatment for PTB and delivery was significantly longer 
when nifedipine was used [44]. Oral nicardipine is additionally an effective and well-tolerated 
tocolytic agent. It is able to arrest PTB more rapidly than parenteral magnesium sulphate [45]. 
Nicardipine was earlier found to be as effective as salbutamol in the treatment of PTB, and it was 
suggested to have advantages especially in cases of pregnancy accompanied by hypertension, diabetes 
or maternal cardiopathy [46]. A comparison of nicardipine with salbutamol in a small Tunisian study 
revealed no significant difference in the efficacies of the two compounds as concerns the average time 
for the disappearance of uterine contractions. However, fewer secondary adverse effects were detected 
with nicardipine, which was therefore proposed as the tocolytic of first choice [47]. 
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4. Side-Effects of CCBs during Tocolysis 
CCBs are generally well tolerated. The most frequent maternal side-effect is headache which is 
associated with the transient hypotension caused by the loading doses [48]. Maternal tachycardia is the 
second most frequently reported adverse events following nifedipine therapy. Besides maternal 
headache, anxiety and vomiting are other frequent side-effects described for nifedipine [49]. As minor 
side-effects, nifedipine may cause palpitation and flushing during tocolysis, but these occur in fewer 
than 10% of the patients [50]. Nifedipine does not influence foetal movement, heart rate or blood flow 
and thus appears to have no direct adverse foetal effects [51]. It is known that the side-effects of the 
drug do not correlate with its plasma level. The adverse reactions can occur in a wide range of 
nifedipine plasma concentrations (6–101 ng/mL), and therefore there is no need to adjust the dose of 
nifedipine to body weight, body mass index or gestational age [52]. 
Nifedipine was suspected of being responsible for severe dyspnoea in seven patients with multiple 
pregnancies. It was hypothesized that the complications were due to the imbalance in the 
ventilation/perfusion of the lungs in consequence of the diaphragm being elevated due to the 
pregnancy. These changes are usually more pronounced in twin pregnancies. The administration of 
nifedipine resulted in a ventilation-perfusion discrepancy and dyspnoea. These observations question 
the safety of nifedipine as a tocolytic agent in patients with multiple pregnancies [53]. Additionally, 
tocolysis with oral nifedipine has been reported to be responsible for maternal pulmonary oedema [54]. 
A comparison of the side-effects of nifedipine and nicardipine revealed that the patients in the 
nicardipine-treated group had significantly more side-effects (31% versus 16% for the nifedipine 
group), although the hypotensive effect of nifedipine was higher [55]. 
Maternal pulmonary oedema induced by the infusion of nicardipine was reported in five pregnant 
women during tocolysis. Therapy was discontinued immediately after the diagnosis, but two patients 
required admission to the intensive care unit [56]. Three other cases of maternal pulmonary oedema during 
PTB were associated with the combination of salbutamol and intravenous nicardipine. It was recommended 
that the association of CCBS and beta-agonists for the treatment of PTB should be avoided [57]. 
5. Tocolytic Effect of CCBs in Combination with Other Drugs 
The idea of combined tocolytic therapy with nifedipine is not new. The first report on effective 
tocolysis with a combination of nifedipine and beta-mimetic terbutaline was published in 1985 [58]. 
The effect was dramatic; the duration of pregnancy was delayed for 2 months without any significant 
side-effects. Unfortunately, this successful treatment was carried out on only one patient. The efficacy 
of the combination of nifedipine and salmeterol was also proved in a hormonally-induced PTB model 
involving rat and human myometrial strips from caesarean sections in term pregnancies [29]. These 
promising results were overshadowed by findings of clinical disadvantages of the combination of 
CCBs and β-mimetics, e.g., possible increases in the risk of maternal myocardial infarction and 
pulmonary oedema. As mentioned earlier, the CCBs are able to elicit respiratory problems in 
monotherapy, and this property is retained when they are applied in combination with other drugs, 
such as glucocorticoids and atosiban, especially in multiple pregnancies [59]. Interestingly, a recent 
study has revealed that atosiban alone is able to induce dyspnoea and pulmonary oedema in multifoetal 
pregnancies [60]. Although some authors suggest that the combination of CCBs and β-mimetics should 
be avoided, this may be restricted to twin pregnancies and maternal cardiovascular disorders. 
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One study has been carried out to investigate the efficacy of combinations of CCBs and oxytocin 
antagonists for tocolysis. The combination atosiban + nifedipine exerts on additive tocolytic effect on 
the contractility of myometrial strips in both pre-term and term patients. Surprisingly, the combination 
nifedipine + celecoxib exhibited a weaker effect than that of nifedipine alone [61]. The combination of 
nifedipine and atosiban may therefore merit testing in clinical studies. 
P4 analogues have been re-introduced into tocolytic therapy in the past decade as preventive compounds 
against PTB. For women with a history of spontaneous PTB, P4 reduces the incidence of PTB before 
34 weeks, but has no beneficial effect in multiple pregnancies or in the event of a short cervix [62]. 
P4 pretreatment has been found to alter the structure of Ca2+ channels, promoting the expression of 
the less sensitive form of the channel, and to weaken the tocolytic effect of nifedipine in pregnant  
rats [20,29]. The tocolytic effect of the combination of 17--hydroxyprogesterone caproate and 
nifedipine was not superior to that of nifedipine alone in a randomized clinical trial [63]. This result 
suggests that P4 treatment probably does not worsen the tocolytic efficacy of CCBs in humans. The 
modification of the tocolytic effect of nifedipine by other compounds and the potential risks of the 
combinations are indicated in Table 3. 
Table 3. Myometrial effects of different combinations of nifedipine. 
Combination Change in myometrial relaxation  Risk of combination 
Nifedipine + ritodrine increased (in both human and animal studies in vivo) 
pulmonary oedema, myocardial 
infarction 
Nifedipine + atosiban increased (in a human study in vitro) no information (data from in vitro experiments only) 
Nifedipine + celecoxib decreased (in a human study in vitro) no information (data from in vitro experiments only) 
Nifedipine + progesterone decreased (in an animal study in vivo) unchanged (in a human study in vivo) 
no special risk as compared with 
nifedipine monotherapy 
6. Conclusions 
CCBs are increasingly used for tocolysis, although officially they are not licensed for this purpose. 
Their efficacy is at least equivalent to that of the traditionally used drugs, but their adverse effects 
seem to be milder and better tolerated than those of beta-adrenergic agonists and not more severe than 
those of oxytocin antagonists. Unfortunately, the CCBs in monotherapy are not better than other 
tocolytics in long-term tocolysis (pregnancy maintenance). 
The effects of nifedipine in tocolytic therapy may possibly be intensified through their combination 
with other compounds. Their efficacy may be enhanced by low concentrations of β2-mimetics. However, 
the administration of β2-adrenergic agonists cannot precede that of nifedipine. There are a number of 
clinical findings that warn against the combination of these two groups in cases of multiple 
pregnancies and maternal cardiovascular disorders. On the other hand, their combination may be 
investigated in single pregnancies that require tocolysis. With regard to the limited nature of the 
information available from preclinical studies, a trial relating to the combined tocolytic effect of CCBs 
and atosiban may be reasonable. 
Overall, it may be concluded that DHP CCBs should remain one of the most important group of 
drugs for the rapid inhibition of premature uterine contractions. There is an urgent need for an updated 
systematic review (e.g., according to the principles of Cochrane reviews) on the clinical application of 
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CCBs in premature labour. Additionally, further clinical studies are required to investigate how to 
enhance their efficacy in combination with other drugs. 
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